By Finance Pulse in biotech —

Pfizer Ends Partnership with Sangamo on Hemophilia A Therapy

Pfizer terminates its partnership with Sangamo, citing limited interest in advancing another hemophilia A gene therapy. Explore the implications for biotech innovation.

A sleek, futuristic illustration of a DNA strand with a backdrop of pharmaceutical symbols and corpo
Pfizer Ends Partnership with Sangamo on Hemophilia A Therapy

Pfizer decided to end its partnership with Sangamo, citing limited interest in an additional hemophilia A gene therapy.

Source